Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Scienture Holdings, Inc. entered into Amended and Restated Agreement and Plan of Merger with Superlatus, Inc. valued at 30,821,941 shares of Company stock at $7.30 per share, comprised of 136,441 shares of common stock ( (effective 2023-07-14).
- Action
- entry
- Agreement
- merger
- Counterparty
- Superlatus, Inc.
- Value
- 30,821,941 shares of Company stock at $7.30 per share, comprised of 136,441 shares of common stock (
- Effective
- 2023-07-14
Exact text from the filing
As previously disclosed, on June 30, 2023, TRxADE HEALTH, Inc., a Delaware corporation (the “Company” or “MEDS”), entered into an Agreement and Plan of Merger (the “Original Merger Agreement”) with Superlatus, Inc., a U.S.-based holding company of food products and distribution capabilities (“Superlatus”). On July 14, 2023, the Company and Superlatus entered into an Amended and Restated Agreement and Plan of Merger (the “A&R Merger Agreement”; the transactions contemplated thereby, the “Merger”), which amends the merger consideration payable to the shareholders of Superlatus and adds the issuance of non-transferrable rights to receive shares of common stock of the Company at no cost to the shareholders of the Company in connection with the Merger.
View on SEC.gov